RadNet Inc
Change company Symbol lookup
Select an option...
RDNT RadNet Inc
PNM PNM Resources Inc
ALB Albemarle Corp
AMBC Ambac Financial Group Inc
ASUR Asure Software Inc
MRK Merck & Co Inc
AMR Alpha Metallurgical Resources Inc
AAL American Airlines Group Inc
ADMS Adamas Pharmaceuticals Inc
MVIS MicroVision Inc
Go

Health Care : Health Care Providers & Services | Small Cap Blend
Company profile

RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2016, the Company operated directly or indirectly through joint ventures, 305 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. As of December 31, 2016, the Company had in operation 257 MRI systems, 157 CT systems, 47 PET or combination PET/CT systems, 48 nuclear medicine systems, 479 X-ray systems, 279 mammography systems, 551 ultrasound systems and 104 fluoroscopy systems.

Closing Price
$22.80
Day's Change
-0.47 (-2.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
23.54
Day's Low
22.27
Volume
(Heavy Day)
Volume:
304,097

10-day average volume:
176,491
304,097

NVIDIA Partners with Schrodinger to Further Accelerate Drug Discovery Worldwide

2:49 pm ET April 12, 2021 (Globe Newswire) Print

GTC -- NVIDIA today announced a strategic partnership with Schrodinger that harnesses NVIDIA DGX A100(TM) systems to further expand the speed and accuracy of Schrodinger's computational drug discovery platform and enable rapid, accurate evaluation of billions of molecules for potential development of therapeutics.

The companies will optimize Schrodinger's software platform -- designed to model and predict the properties of novel molecules -- for the NVIDIA DGX SuperPOD(TM), which is built with NVIDIA DGX A100 systems and NVIDIA InfiniBand HDR networking.

The work includes the physics-based modeling in Schrodinger's product suite, as well as support for NVIDIA Clara(TM) Discovery, a collection of state-of-the-art AI frameworks, applications and pre-trained models for the most advanced computational drug discovery. Additionally, the companies will partner on scientific and research breakthroughs to further advance physics-based computing and machine learning for drug discovery.

For each potential drug candidate, Schrodinger routinely evaluates tens of thousands of molecules with its most computationally intensive physics-based approaches. This requires hundreds of thousands of hours of GPU time on high-performance computers.

Through the collaboration, the entire pharmaceutical industry comprising over 3,000 companies -- from startups to multinationals -- will be able to further accelerate drug discovery at supercomputing scale. The joint solution will enable companies of all sizes to simulate molecular combinations with physics and AI to identify and optimize the most promising compounds for potential therapeutic use. Pharmaceutical companies can run this research on their own easy-to-deploy private clouds featuring the Schrodinger platform running on NVIDIA DGX SuperPOD, which is available to install on premises or in a colocation facility.

"The predictive modeling built into our platform is designed to dramatically expand and accelerate the search for high-quality therapeutic molecules, and NVIDIA is a key technology partner in this work," said Patrick Lorton, chief technology officer at Schrodinger. "Our advanced computational software helps the world's biggest pharma companies explore more of the chemical space and reach high-quality candidates more quickly, with far less compute cost, than traditional methods. We're proud to be working with NVIDIA to make that process run even more smoothly."

NVIDIA research and engineering teams are working to advance and optimize the Schrodinger suite to take advantage of the NVIDIA Ampere architecture and its Multi-Instance GPU technology. Customers will be able to easily deploy Schrodinger software on a single DGX system or a cluster of 20 or more to create a DGX SuperPOD. This allows scaling the Schrodinger platform to dozens of drug programs and screening and evaluating billions of molecules a week.

"Computational drug discovery is improving accuracy with Schrodinger's advanced combination of simulation with machine learning," said Kimberly Powell, vice president of healthcare at NVIDIA. "Together, we're giving the pharmaceutical industry a scientific instrument that delivers super-high-throughput lead generation to improve and accelerate the success of drug candidates."

About NVIDIA

NVIDIA's (NASDAQ: NVDA) invention of the GPU in 1999 sparked the growth of the PC gaming market and has redefined modern computer graphics, high performance computing and artificial intelligence. The company's pioneering work in accelerated computing and AI is reshaping trillion-dollar industries, such as transportation, healthcare and manufacturing, and fueling the growth of many others. More information at https://nvidianews.nvidia.com/.

For further information, contact:

Janette Ciborowski

NVIDIA Corporation

+1-734-330-8817

jciborowski@nvidia.com

Certain statements in this press release including, but not limited to, statements as to: the benefits and impact of NVIDIA and Schrodinger partnering and what it will enable; the companies optimizing Schrodinger's software platform; the benefits, impact and performance of our products and technologies; the companies advancing physics-based computing and machine learning for drug discovery; the work that goes into evaluating drug candidates; the collaboration enabling the pharmaceutical industry to accelerate drug discovery at scale and how they can use this technology; the availability of the Schrodinger platform; the benefits of predictive modeling built into the Schrodinger platform; Schrodinger's software helping the biggest companies; how NVIDIA is contributing to Schrodinger's work and advancing its suite of products; how customers can deploy Schrodinger software and what it allows; and how computational drug discovery is improving are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic conditions; our reliance on third parties to manufacture, assemble, package and test our products; the impact of technological development and competition; development of new products and technologies or enhancements to our existing product and technologies; market acceptance of our products or our partners' products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of our products or technologies when integrated into systems; as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company's website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

(C) 2021 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, DGX A100, NVIDIA Clara and NVIDIA DGX SuperPOD are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other company and product names may be trademarks of the respective companies with which they are associated.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/93c4dd86-d822-42cd-85be-0d9355a4d051

https://ml.globenewswire.com/media/ad3b9553-6933-40b1-adfd-2ed199cd141c/small/nvidia-logo-jpg.jpg

https://ml.globenewswire.com/media/ad3b9553-6933-40b1-adfd-2ed199cd141c/small/nvidia-logo-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.